Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit

Noramco, a leading global active pharmaceutical ingredients manufacturer, specializing in controlled substances, announced it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.

Scroll to Top